Next Article in Journal
Isolation of Circulating Tumor Cells by Dielectrophoresis
Next Article in Special Issue
Stat3 and Gap Junctions in Normal and Lung Cancer Cells
Previous Article in Journal / Special Issue
Genetic Interactions of STAT3 and Anticancer Drug Development
Open AccessReview

The Role of STAT3 in Thyroid Cancer

Department of Biochemistry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
Author to whom correspondence should be addressed.
Cancers 2014, 6(1), 526-544;
Received: 16 December 2013 / Revised: 15 February 2014 / Accepted: 27 February 2014 / Published: 6 March 2014
(This article belongs to the Special Issue STAT3 Signalling in Cancer: Friend or Foe)
PDF [403 KB, uploaded 6 March 2014]


Thyroid cancer is the most common endocrine malignancy and its global incidence rates are rapidly increasing. Although the mortality of thyroid cancer is relatively low, its rate of recurrence or persistence is relatively high, contributing to incurability and morbidity of the disease. Thyroid cancer is mainly treated by surgery and radioiodine remnant ablation, which is effective only for non-metastasized primary tumors. Therefore, better understanding of the molecular targets available in this tumor is necessary. Similarly to many other tumor types, oncogenic molecular alterations in thyroid epithelium include aberrant signal transduction of the mitogen-activated protein kinase, phosphatidylinositol 3-kinase/AKT (also known as protein kinase B), NF-кB, and WNT/β-catenin pathways. However, the role of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT3) pathway, a well-known mediator of tumorigenesis in different tumor types, is relatively less understood in thyroid cancer. Intriguingly, recent studies have demonstrated that, in thyroid cancer, the JAK/STAT3 pathway may function in the context of tumor suppression rather than promoting tumorigenesis. In this review, we provide an update of STAT3 function in thyroid cancer and discuss some of the evidences that support this hypothesis. View Full-Text
Keywords: thyroid cancer; JAK; STAT3; interleukin 6; leukemia inhibitory factor thyroid cancer; JAK; STAT3; interleukin 6; leukemia inhibitory factor

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Sosonkina, N.; Starenki, D.; Park, J.-I. The Role of STAT3 in Thyroid Cancer. Cancers 2014, 6, 526-544.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top